Companies Dominating the Microbiome Therapeutics Landscape
- YSOPIA Bioscience
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- 4D pharma plc
- Enterome
- BiomX Inc.
- Ferring International Center S.A.
- Vedanta Biosciences, Inc.
- Seres Therapeutics, Inc.
- Assembly Biosciences, Inc.
- Synlogic
- Finch Therapeutics Group, Inc.
Browse Key Market Insights with Data Illustration:
In the News
-
Enterome has introduced the world's first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics therapeutic cancer vaccine, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Ferring International Center S.A. has received approval from the U.S. FDA for REBYOTA (fecal microbiota, live-jslm). It is a novel first-in-class microbiota-based live biotherapeutic denoted for the inhibition of recurrence of Clostridioides difficile infection (CDI) in individuals of 18 years of age and older, following antibiotic treatment for recurrent CDI.
